NEW YORK (GenomeWeb News) – eBioscience recorded $70.9 million in revenues during 2011, leading to a profit of $9.6 million, Affymetrix disclosed in a regulatory filing today.

Waiting to complete its $315 million buy of the San Diego-based flow cytometry and immunoassay reagents firm, Affy today said in a document filed with the US Securities and Exchange Commission that eBioscience's 2011 revenues increased 9 percent over 2010 revenues of $65.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.